Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double‐blind, multicenter, therapeutic confirmatory, phase III clinical trial
The Journal of Clinical Hypertension · 2024
DOI: 10.1111/jch.14778 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Hypertension, 2024. Verfasst von Chan Joo Lee und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Dyslipidemias, Ezetimibe, Hypertension, Rosuvastatin Calcium. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
This study aimed to compare and evaluate the efficacy of the blood pressure (BP) control and cholesterol‐lowering effects and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe versus rosuvastatin and ezetimibe double therapy or telmisartan single therapy in dyslipidemia patients with hypertension. After a wash‐out/therapeutic lifestyle change period of ≥4 weeks, a total of 100 eligible patients were randomized and received one of three treatments for 8 weeks: (1) telmisartan 80 mg/rosuvastatin 20 mg/ezetimibe 10 mg (TRE), (2) rosuvastatin 20 mg/ezetimibe 10 mg (RE), or (3) telmisartan 80 mg (T). The primary endpoint was the efficacy evaluation of TRE by comparing changes in mean sitting systolic blood pressure (msSBP) and mean percentage change in low‐density lipoprotein‐C (LDL‐C) from baseline after 8 weeks of treatment. The least square (LS) mean (SE) changes in msSBP at 8 weeks compared with baseline were −23.02 (3.04) versus −7.18 (3.09) mmHg in the TRE and RE groups, respectively ( p < .0001), and −25.80 (2.74) versus −14.92 (2.65) mmHg in the TRE and T groups, respectively ( p = .0005). The percentage changes in the mean (SD) LDL‐C at 8 weeks compared with baseline were −54.97% (3.49%) versus −0.17% (3.23%) in the TRE and T groups, respectively ( p < .0001). No serious adverse events occurred, and no statistically significant differences in the incidence of overall AEs and adverse drug reactions occurred among the three groups. TRE therapy significantly decreased msSBP and LDL‐C compared to RE or T therapy with comparable safety and tolerability profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
- Department of Cardiology, Gil Hospital, Gachon University, Incheon, South Korea.
- Division of Cardiology, Department of Internal Medicine, Bucheon St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
- Department of Cardiology, Kyung Hee University Hospital at Gangdong, Seoul, South Korea.
- Department of Internal Medicine, Kyung Hee University College of Medicine, Kyung Hee University Medical Center, Seoul, South Korea.
- Division of Interventional Cardiology, Cardiovascular Center, Korea University Guro Hospital, Seoul, South Korea.
ORCID-Profile: Chan Joo Lee, Jong Shin Woo
Zitieren
APA
Lee, C. J., Kang, W. C., Ihm, S. H., Sohn, I. S., Woo, J. S., Kim, J. W., Hong, S. J., Choi, J. H., Suh, J. W., Seo, J. B., Doh, J. H., Son, J. W., Park, J. H., Lee, J. H., Hong, Y. J., Heo, J. H., Shin, J., & Kang, S. M. (2024). Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double‐blind, multicenter, therapeutic confirmatory, phase III clinical trial. The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.14778
Vancouver
Lee CJ, Kang WC, Ihm SH, Sohn IS, Woo JS, Kim JW, et al. Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double‐blind, multicenter, therapeutic confirmatory, phase III clinical trial. The Journal of Clinical Hypertension. 2024. doi:10.1111/jch.14778
BibTeX
@article{Lee2024,
author = {Lee, Chan Joo and Kang, Woong Chol and Ihm, Sang Hyun and Sohn, Il Suk and Woo, Jong Shin and Kim, Jin Won and Hong, Soon Jun and Choi, Jung Hyun and Suh, Jung-Won and Seo, Jae-Bin and Doh, Joon-Hyung and Son, Jung-Woo and Park, Jae-Hyeong and Lee, Ju-Hee and Hong, Young Joon and Heo, Jung Ho and Shin, Jinho and Kang, Seok-Min},
title = {Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double‐blind, multicenter, therapeutic confirmatory, phase III clinical trial},
journal = {The Journal of Clinical Hypertension},
year = {2024},
doi = {10.1111/jch.14778}
}
EUVIMED